Abstract
Aims and background. This retrospective analysis reports the outcomes obtained with an original once-weekly stereotactic radiotherapy fractionation given to patients affected by evolving oligometastases from different solid malignancies. Methods. From 2009 to 2011, patients with symptomatic and/or evolving oligometastases were submitted to a median 5-fraction cycle of stereotactic radiotherapy of one fraction per week in order to exploit a radiobiological rationale designed to increase the therapeutic index. Individual fractionation was mainly planned according to patient performance status, oligometastasis size and site, and record of previous irradiation in the same site. Results. Thirty-six patients in stage IV UICC-TNM affected by oligometastases were treated with image-guided intensity-modulated stereotactic tomotherapy with a single weekly radiation. Median age was 70 years (range, 34-89). The median weekly single dose, number of fractions and overall total radiation dose were 7 Gy, 5 fractions and 35 Gy, respectively. Thirty-five (97%) patients completed the treatment schedule. No patient suffered mild or severe radiation-related side effects. Twenty-one (87%) of 24 patients with local pain had complete symptomatic response within 30 days following the end of radiotherapy. Local control assessed at imaging after stereotactic radiotherapy was evidenced in 30 (83%) patients. Median time to response after the end of radiotherapy was 40 days. Conclusions. The original radiotherapy regimen delivering only a single stereotactic dose per week seems to be highly feasible with an interesting high efficacy rate in patients with oligometastases from different solid tumors. Overall, the once-weekly treatment was very compliant in an advanced cancer stage especially for elderly and frail patients.
| Original language | English |
|---|---|
| Pages (from-to) | 159-163 |
| Number of pages | 5 |
| Journal | Tumori |
| Volume | 99 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Mar 2013 |
Fingerprint
Keywords
- Oligometastases
- Onceweekly fractionation
- Stereotactic radiotherapy
- Tomotherapy
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Once-weekly stereotactic radiotherapy for patients with oligometastases : Compliance and preliminary efficacy. / Corvò, Renzo; Lamanna, Giorgio; Vagge, Stefano; Belgioia, Liliana; Bosetti, Davide; Aloi, Deborah; Timon, Giorgia; Bacigalupo, Almalina.
In: Tumori, Vol. 99, No. 2, 03.2013, p. 159-163.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Once-weekly stereotactic radiotherapy for patients with oligometastases
T2 - Compliance and preliminary efficacy
AU - Corvò, Renzo
AU - Lamanna, Giorgio
AU - Vagge, Stefano
AU - Belgioia, Liliana
AU - Bosetti, Davide
AU - Aloi, Deborah
AU - Timon, Giorgia
AU - Bacigalupo, Almalina
PY - 2013/3
Y1 - 2013/3
N2 - Aims and background. This retrospective analysis reports the outcomes obtained with an original once-weekly stereotactic radiotherapy fractionation given to patients affected by evolving oligometastases from different solid malignancies. Methods. From 2009 to 2011, patients with symptomatic and/or evolving oligometastases were submitted to a median 5-fraction cycle of stereotactic radiotherapy of one fraction per week in order to exploit a radiobiological rationale designed to increase the therapeutic index. Individual fractionation was mainly planned according to patient performance status, oligometastasis size and site, and record of previous irradiation in the same site. Results. Thirty-six patients in stage IV UICC-TNM affected by oligometastases were treated with image-guided intensity-modulated stereotactic tomotherapy with a single weekly radiation. Median age was 70 years (range, 34-89). The median weekly single dose, number of fractions and overall total radiation dose were 7 Gy, 5 fractions and 35 Gy, respectively. Thirty-five (97%) patients completed the treatment schedule. No patient suffered mild or severe radiation-related side effects. Twenty-one (87%) of 24 patients with local pain had complete symptomatic response within 30 days following the end of radiotherapy. Local control assessed at imaging after stereotactic radiotherapy was evidenced in 30 (83%) patients. Median time to response after the end of radiotherapy was 40 days. Conclusions. The original radiotherapy regimen delivering only a single stereotactic dose per week seems to be highly feasible with an interesting high efficacy rate in patients with oligometastases from different solid tumors. Overall, the once-weekly treatment was very compliant in an advanced cancer stage especially for elderly and frail patients.
AB - Aims and background. This retrospective analysis reports the outcomes obtained with an original once-weekly stereotactic radiotherapy fractionation given to patients affected by evolving oligometastases from different solid malignancies. Methods. From 2009 to 2011, patients with symptomatic and/or evolving oligometastases were submitted to a median 5-fraction cycle of stereotactic radiotherapy of one fraction per week in order to exploit a radiobiological rationale designed to increase the therapeutic index. Individual fractionation was mainly planned according to patient performance status, oligometastasis size and site, and record of previous irradiation in the same site. Results. Thirty-six patients in stage IV UICC-TNM affected by oligometastases were treated with image-guided intensity-modulated stereotactic tomotherapy with a single weekly radiation. Median age was 70 years (range, 34-89). The median weekly single dose, number of fractions and overall total radiation dose were 7 Gy, 5 fractions and 35 Gy, respectively. Thirty-five (97%) patients completed the treatment schedule. No patient suffered mild or severe radiation-related side effects. Twenty-one (87%) of 24 patients with local pain had complete symptomatic response within 30 days following the end of radiotherapy. Local control assessed at imaging after stereotactic radiotherapy was evidenced in 30 (83%) patients. Median time to response after the end of radiotherapy was 40 days. Conclusions. The original radiotherapy regimen delivering only a single stereotactic dose per week seems to be highly feasible with an interesting high efficacy rate in patients with oligometastases from different solid tumors. Overall, the once-weekly treatment was very compliant in an advanced cancer stage especially for elderly and frail patients.
KW - Oligometastases
KW - Onceweekly fractionation
KW - Stereotactic radiotherapy
KW - Tomotherapy
UR - http://www.scopus.com/inward/record.url?scp=84881250666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84881250666&partnerID=8YFLogxK
U2 - 10.1700/1283.14186
DO - 10.1700/1283.14186
M3 - Article
VL - 99
SP - 159
EP - 163
JO - Tumori
JF - Tumori
SN - 0300-8916
IS - 2
ER -